America's Medicine Cabinet: Unpacking the Tariffs Debate and Our Global Drug Reliance
The Cost Conundrum: Unpacking Massachusetts' Sky-High Healthcare Bills
Essential Medicines: DRAP Dispels Price Hike Rumors Amid Global Uncertainty
The Unforeseen Ripple: How Trump's Drug Pricing Push Could Have Raised Global Costs
A Game Changer for Health: Generic Semaglutide Slashes Prices in India, Offering New Hope
Global Turmoil Squeezes India's Pharma: Drugmakers Plead for Input Price Caps
The Uncharted Alliance: Klotho Neurosciences Forges Unexpected Path with Greenland Mining Giant
The Persistent Ache: Why Affordable Drug Prices Remain an Elusive Dream for Americans
An Unexpected Turn: America's Drug Price Paradox
A Real Plan to Tackle Soaring Drug Costs
Trump Launches TrumpRx: A Digital Crusade Against Sky-High Drug Prices
AstraZeneca's Bold Bet: Charging Hard into China's Obesity Drug Race and Beyond
The Cost of Cures: Unpacking America's Enduring Drug Price Predicament
Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push
The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices
Vinay Prasad Sounds the Alarm: Media Missteps and Harvard’s Choices Are Hurting Biotech
Rethinking Drug Costs: Why Quick Fixes Might Hurt More Than Help
A New Prescription for Prosperity: US & UK Seal Zero-Tariff Pharma Deal
A Vital Step Forward: Sarepta's Duchenne Drug Secures Key Testing Clearance
A New Era for Drug Prices: How Medicare's Negotiation Power is Reshaping Healthcare
The Unfolding Saga of GLP-1 Drugs: A Potential Game-Changer for Alzheimer's?
The Evolving Landscape of Biotech Innovation and Investment
Wegovy's Reckoning: Novo Nordisk's CEO Digs In as the Weight Loss Market Heats Up
The Wegovy Paradox: Cheaper, Yet Still Out of Reach for Many
The Cost of Cures: Unraveling the High Price Tag on Biologic Drugs and the Persistent Push for Affordability
The Great Pharmaceutical Gridlock: How Patents Keep Prices Sky-High and Biosimilars at Bay
A Grand Bargain for Health? The Looming Question of Obesity Drugs and Who Pays.
The GLP-1 Gambit: Pharma Giants, Trump, and the High Stakes of Drug Prices
The Great Negotiation: Big Pharma, Weight Loss, and the White House
The Ghost in the Machine: How Trump's Drug Price Transparency Memo Almost Changed Everything—But Didn't
The Astonishing Disparity: Why Miebo's Price Tag is a World Apart Across the Atlantic
The Quiet Revolution: How the FDA is Finally Taking Aim at Sky-High Drug Prices
Biotech's Pulse Check: AI Rises, a Cancer Test Stumbles, and a Rare Disease Shines
The Biotech Beat: Unpacking a Week of Breakthroughs, Billions, and Big Bets
Biotech's Pulse: Gene-Editing's Leap, Cancer's New Fights, and What's Stirring the Industry
The Great Weight Shift: Biotech's Quest for What's Next in Obesity Care
The Shadow Returns: What Trump's Drug Pricing Encore Means for Your Medicine Cabinet
Trump Unleashes Trade Weapon Against Global Partners Over 'Unfair' Drug Prices
Biotech's Vanguard: Novo Nordisk, Omeros, and GSK Charting New Territories in Medical Innovation
AstraZeneca's Landmark Deal: Lowering Drug Prices for Medicaid Under Trump Administration Agreement
Revolutionizing Healthcare: Trump's Bold Stance on Lowering Prescription Drug Costs
President Trump's Landmark Initiative to Tackle Skyrocketing Prescription Drug Costs
Trump's Bold New Blueprint: Unveiling Ambitious Plans to Slash Prescription Drug Costs